Mineral Metabolism Disorder - Pipeline Insight, 2024

This “Mineral Metabolism Disorder - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Mineral Metabolism Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mineral Metabolism Disorder Understanding

Mineral Metabolism Disorder: Overview

Mineral Metabolism Disorder is a disease in which there are abnormal levels of minerals (either too much or too little) in the body. Mineral metabolic disorders may be genetic or arise as a result of certain clinical conditions pertaining to starvation, excess alcohol consumption, diarrhea, and diet disorders. Minerals are very important for the human body. They are essential for the proper function of cells, tissues, and organs. Mineral Metabolism Disorders can lead to variety of other disorders like nephrocalcinosis, hyperparathyroidism, Cushing’s syndrome, Menkes syndrome, Wilson’s disease etc.

Symptoms
The symptoms of Mineral Metabolism Disorder include:

• Anxiety
• Blood pressure changes
• Chronic fatigue
• Dizziness, especially when standing up suddenly
• Changes in appetite or bodyweight
• Headaches
• Muscle weakness, aches or twitching
• Extreme thirst
• Heart palpitations or irregular heartbeats
• Digestive issues such as diarrhea or constipation
• Joint pain or numbness

Diagnosis
A diagnosis of Mineral Metabolism Disorder is made through blood test, urine test or other lab test, for example toxic elements profile, advanced metabolic panel, metabolic profile, and electrolyte test profile to check for mineral abnormalities. In some cases, an ultrasound, abdominal X-rays, or an EKG test is done.

Treatment
The Mineral Metabolism Disorder can be treated through Intravenous (IV) fluids, changes in diet, or by taking mineral or vitamin supplements. The ideal treatment for majority of mineral metabolism disorders is to maintain a healthy lifestyle and follow a proper balanced diet. Novel treatments are under development for treating disorders related to Mineral Metabolism.

Mineral Metabolism Disorder Emerging Drugs Chapters

This segment of the Mineral Metabolism Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mineral Metabolism Disorder Emerging Drugs

Hexasodium phytate: Sanifit Hexasodium phytate (SNF472) is a selective calcification inhibitor and inhibits the development and progression of ectopic calcifications by binding to the growth sites of hydroxyapatite (HAP) crystals, the main component of calcification deposits. Sanifit has obtained orphan drug status from the FDA and EMA for SNF472 as an investigational treatment forcalciphylaxis.

Mineral Metabolism Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Mineral Metabolism Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mineral Metabolism Disorder

There are approx. 5+ key companies which are developing the therapies for Mineral Metabolism Disorder. The companies which have their Mineral Metabolism Disorder drug candidates in the most advanced stage, i.e. phase III include, Sanifit.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Mineral Metabolism Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mineral Metabolism Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mineral Metabolism Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mineral Metabolism Disorder drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Mineral Metabolism Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Mineral Metabolism Disorder.

Mineral Metabolism Disorder Report Insights

• Mineral Metabolism Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mineral Metabolism Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mineral Metabolism Disorder drugs?
• How many Mineral Metabolism Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mineral Metabolism Disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mineral Metabolism Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mineral Metabolism Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Medtronic
• Eli Lilly
• Sanifit
• Sanofi

Key Products

• Dibotermin alfa
• Blosozumab
• Hexasodium phytate
• Ataciguat

This product will be delivered within 1-3 business days.